Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: a case report and review of the literature.
A combination of a paclitaxel and platinum analog is currently the standard first-line chemotherapy for women with ovarian cancer, with response rates of 20-37%. As patients who relapse have a poor prognosis and treatment options are limited, there is an urgent need to develop new agents with novel mechanisms of action for use as a second-line, non-cross-resistant chemotherapy in ovarian cancer. In this report, we describe a patient with platinum/paclitaxel-refractory ovarian cancer who received topotecan and reached long-term stabilization of her disease. The patient was administered 1.5 mg/m2 topotecan for five days in 17 cycles. She was also given granulocyte colony-stimulating factor (G-CSF) support to prevent severe granulocytopenia; no hematologic toxic effect was experienced. Her quality of life was good throughout the treatment, and also her daily activities were unaffected.
Balat
O
O
Department of Obstetrics and Gynecology, University of Gaziantep, Medical School Gaziantep, Turkey.
Ugur
M G
MG
D000231:Adenocarcinoma, Papillary / Q000188:drug therapy* / Q000601:surgery; D000380:Agranulocytosis / Q000139:chemically induced / Q000188:drug therapy; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017239:Paclitaxel / Q000627:therapeutic use; D017671:Platinum Compounds / Q000627:therapeutic use; D011788:Quality of Life; D019772:Topotecan / Q000009:adverse effects / Q000627:therapeutic use*
D017671:Platinum Compounds; D016179:Granulocyte Colony-Stimulating Factor; D019772:Topotecan; D017239:Paclitaxel